Serum amyloid a truncations in type 2 diabetes mellitus

PLoS One. 2015 Jan 21;10(1):e0115320. doi: 10.1371/journal.pone.0115320. eCollection 2015.

Abstract

Methods: Using mass spectrometric immunoassay, the abundance of SAA truncations relative to the native variants was examined in plasma of 91 participants with type 2 diabetes and chronic kidney disease and 69 participants without diabetes.

Results: The ratio of SAA 1.1 (missing N-terminal arginine) to native SAA 1.1 was lower in diabetics compared to non-diabetics (p = 0.004), and in males compared to females (p<0.001). This ratio was negatively correlated with glycated hemoglobin (r = -0.32, p<0.001) and triglyceride concentrations (r = -0.37, p<0.001), and positively correlated with HDL cholesterol concentrations (r = 0.32, p<0.001).

Conclusion: The relative abundance of the N-terminal arginine truncation of SAA1.1 is significantly decreased in diabetes and negatively correlates with measures of glycemic and lipid control.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Arginine / metabolism
  • Cholesterol, HDL / blood*
  • Diabetes Mellitus, Type 2 / blood*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Serum Amyloid A Protein / metabolism*

Substances

  • Cholesterol, HDL
  • Serum Amyloid A Protein
  • Arginine